Eurofins Scientific


Top-line growth improves in Q3

08/11/19 -"Eurofins reported reassuring top-line growth in Q3 FY19 – the performance was spread across all geographies except for the UK. The growth is likely to be sustained in Q4 FY19, in our opinion. ..."

Pages
44
Language
English
Published on
08/11/19
You may also be interested by these reports :
26/05/20
We have increased our revenue estimates for Eurofins further, as demand for COVID-19 testing continues to accelerate in the gradually re-opening ...

25/05/20
We have revised our revenue and profitability estimates downwards, incorporating better the COVID-19 impact and currency headwinds from Experian’s ...

21/05/20
Experian clocked strong organic revenue growth in FY19/20 (although the profitability target missed a tad). However, as expected, moving into the ...

07/05/20
Organic sales increased in Q1 20 (+2% vs +7% in Q1 19) despite the high comparative last year and the reduction in economic activity due to the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO